Vizient urges CMS to reconsider home infusion benefit
By HME News Staff
Updated Thu November 8, 2018
IRVING, Texas - Vizient, a member-driven health care performance improvement company and its subsidiary Provista, a supply chain partner for non-acute healthcare delivery organizations, have urged CMS to reconsider its “very narrow interpretation of the new Medicare home infusion benefit. The benefit was finalized in the recently released Home Health Prospective Payment System final rule for 2019. The rule will limit reimbursement for home infusion services to only the day on which the services are furnished by skilled professionals in the individual's home. “Unfortunately, this decision will likely limit patient access to high-quality, low-cost home infusion services,” the groups stated.
Comments